Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dog epilepsy research is 'below par'
chocolate labrador
Epilepsy is the most common chronic neurological condition found in both dogs and people.
RVC carries out the first ever systematic review of AED efficacy

Research on the efficacy of canine epilepsy drugs is well below the expected standard, according to a new study by the Royal Veterinary College (RVC).

The first ever systematic review of canine anti-epilepsy drugs (AEDs) revealed that much of the evidence for medical treatment of the condition was based on "subpar testing".

Researchers from the RVC's canine epilepsy clinic reviewed all data published in peer-reviewed journals and publications, and assessed its reliability. According to their findings, only a few of the studies were relatively unbiased and objective.

To evaluate the reliability of the data, RVC researchers explored the evidence quality, study design, study group size, subject enrolment quality and bias risk.

Dr Dave Brodbelt, senior lecturer in companion animal epidemiology, said: "This systematic review revealed that, in veterinary medicine, the quality of evidence provided by the studies for AEDs' efficacy is not yet at a recommended standard.

"Many studies revealed a potential efficacy of a drug, but then there was a lack of follow-up studies of higher quality confirming the initial positive results."

Epilepsy affects 50,000 dogs and 600,000 people in the UK, making it the most common chronic neurological condition found in both dogs and people.

Professor Holger Volk, clinical director of the RVC Small Animal Referral Hospital, said: "Canine epilepsy is a complex condition and can be very distressing for the dog and their owners, therefore it is immensely important the drug treatments we give to our pets have been properly tested in reliable studies."

In light of the findings, RVC researchers recommend veterinary scientists work together more closely to improve the quality of testing. It is also suggested that scientists forge closer relationships with major stakeholders and funders to reduce the risk of bias.

Veterinary medicine should also take its lead from human epilepsy research, using examples such as the International League Against Epilepsy, which works to advance and distribute knowledge about epilepsy, promote research and education and improve the care available to patients.

To view the RVC's systematic review, published in BMC Veterinary Research Journal, visit:
http://www.biomedcentral.com/1746-6148/10/257/abstract

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.